Analysis Report of China Liver Disease Drug Industry 2015
出 版 商：AskCI
出版日期：2015/01/29
頁 數：195頁
文件格式：PDF
價 格：
USD 3,500 (Single-User License)
USD 3,700 (Hard copy)
USD 3,700 (Hard copy)
Liver damage can cause a series of diseases. According to the different etiology, liver disease can generally be divided into viral liver disease and non-viral liver disease. Non-viral hepatitis mainly includes alcoholic hepatitis, drug-induced hepatitis or toxin-induced hepatitis, metabolism abnormal hepatitis, hepatic calculus, etc. In 2013, there are total 1,251,900 cases of virus hepatitis reported in China, killing 739 people. Among them, the number of hepatitis A, hepatitis B, hepatitis C and hepatitis E reported were 22,200 cases, 963,000 cases, 203,200 cases, 27,900 cases and 35,600 cases respectively.
Liver disease drug market competition of our country is really fierce. China’s liver disease drug market can be divided into imported drugs and home-made drugs according to the drug producing area. Imported drugs are mainly represented by GlaxoSmithKline and Bristol-Myers Squibb, etc.; the main production enterprises of home-made drugs include Chia Tai Tianqing Pharmaceutical Group, TIPR Pharmaceutical Responsible Company, Fujian Cosunter Pharmaceutical Company, etc. Hepatobiliary system drug has gradually become a variety that costs a large amount of money and it is the third largest one that ranks only second to anti-peptic ulcer and diabetes drug in the digestion metabolism category. In terms of the structure of drug, anti-viral drugs and free regulating drugs account for 30% of liver disease drug, auxiliary drugs account for 25% and Chinese medicine account for 36%.
The sales volume of China liver disease drug in hospital market is increasing. Before 2009, as a result of the continuous introduction of new products, new specifications and new dosage form products, the growth of sales was comparatively large, while its growth began to slow down from 2010. On the one hand, it is due to the hepatitis B vaccination rate has been increased significantly in recent years and the decrease of the expansion speed of hepatitis B patients; on the other hand, the growth of sales has entered a smooth stage. The data issued by China Competition Information shows that, the scale of China liver disease drug market is close to RMB 43 billion in 2013.
China has become the world's top country who pays the most social cost for hepatitis B, liver cirrhosis and hepatoma. The data also shows that there are nearly 100 million Chinese among the 350 million hepatitis B carriers, and China accounts for nearly half of the 700,000 or so viral hepatitis related deaths each year. We have a large number of hepatitis B patients, while the growth of hepatitis C patients and alcoholic liver patients has grown rapidly in recent years. The liver disease diagnosis and treatment in our country has a large mass base. Individualized diagnosis and treatment of liver disease came from abroad. It is developed rapidly in our country in recent years, which puts forward higher requirements for the diagnosis of liver disease and the price ratio of drug curative effect. As the application of new diagnostic techniques and new drugs, the market scale of liver disease diagnosis and treatment industrial chain is still expected to grow steadily.
Liver disease drug market competition of our country is really fierce. China’s liver disease drug market can be divided into imported drugs and home-made drugs according to the drug producing area. Imported drugs are mainly represented by GlaxoSmithKline and Bristol-Myers Squibb, etc.; the main production enterprises of home-made drugs include Chia Tai Tianqing Pharmaceutical Group, TIPR Pharmaceutical Responsible Company, Fujian Cosunter Pharmaceutical Company, etc. Hepatobiliary system drug has gradually become a variety that costs a large amount of money and it is the third largest one that ranks only second to anti-peptic ulcer and diabetes drug in the digestion metabolism category. In terms of the structure of drug, anti-viral drugs and free regulating drugs account for 30% of liver disease drug, auxiliary drugs account for 25% and Chinese medicine account for 36%.
The sales volume of China liver disease drug in hospital market is increasing. Before 2009, as a result of the continuous introduction of new products, new specifications and new dosage form products, the growth of sales was comparatively large, while its growth began to slow down from 2010. On the one hand, it is due to the hepatitis B vaccination rate has been increased significantly in recent years and the decrease of the expansion speed of hepatitis B patients; on the other hand, the growth of sales has entered a smooth stage. The data issued by China Competition Information shows that, the scale of China liver disease drug market is close to RMB 43 billion in 2013.
China has become the world's top country who pays the most social cost for hepatitis B, liver cirrhosis and hepatoma. The data also shows that there are nearly 100 million Chinese among the 350 million hepatitis B carriers, and China accounts for nearly half of the 700,000 or so viral hepatitis related deaths each year. We have a large number of hepatitis B patients, while the growth of hepatitis C patients and alcoholic liver patients has grown rapidly in recent years. The liver disease diagnosis and treatment in our country has a large mass base. Individualized diagnosis and treatment of liver disease came from abroad. It is developed rapidly in our country in recent years, which puts forward higher requirements for the diagnosis of liver disease and the price ratio of drug curative effect. As the application of new diagnostic techniques and new drugs, the market scale of liver disease diagnosis and treatment industrial chain is still expected to grow steadily.
Chapter I Related Overview of Liver Disease drug 14
Section I Basic Explanation of Liver Disease 14
I. Classification and Harm of Liver Disease 14
II. Routes of Transmission 14
III. Symptoms of Liver Disease 15
IV. Development Stages of Liver Disease and Prevention and Treatment Measures 16
Section II Viral Hepatitis 17
I. Hepatitis A Virus (HAV) 17
II. Hepatitis B Virus (HBV) 18
III. Hepatitis C Virus (HCV) 20
IV. Hepatitis D Virus (HDV) 21
V. Hepatitis E Virus (HEV) 21
Section III Adiposis Hepatica and Hepatic Fibrosis 22
I. Adiposis Hepatica 22
II. Hepatic Fibrosis 22
Section IV The Clinical Features of Hepatoma 23
Section V Drug-induced Liver Injury 25
I. The Clinical Manifestations of Drug-induced Liver Injury 25
II. The Common Drugs That Are Easy to Cause the Damage of Liver Clinically 26
III. The Precautionary Measures of Drug-induced Liver Injury 27
Chapter II Analysis of the Operation Situation of Global Drugs for the Liver Disease Markets in 2013 29
Section I Analysis of Market Dynamics of Global Drugs for the Liver Disease Markets in 2013 29
I. Japan Has Exploited New Oral Hepatitis C Vaccine 29
II. Gilead Has Developed the New Generation of Hepatitis C Drugs 30
III. The Research of HCV Has Achieved New Breakthrough 30
Section II Analysis of Market Demand of Global Vaccine for the Hepatitis in 2013 31
I. Overview of Global Vaccine for the Hepatitis Market 31
II. Analysis of the Sales Status of the Global Vaccine for the Hepatitis 34
III. Demand Forecast of the Global Vaccine for the Hepatitis Market 34
Section III Analysis of the Application for Patent of the Global Hepatitis B 35
I. The Variation Trend of the Application Quantity for Patents 35
II. Description of Patent Application of Countries or Organizations 36
III. Description of Patent Application of Main Research and Development Production Agencies on Hepatitis B Vaccine 37
V. Analysis of patent technology life cycle 38
Chapter III Analysis of Market Development Environment of China’s Liver Disease Drug Industry in 2013-2014 40
Section I Analysis of China’s Macroeconomic Environment in 2014 40
I. Analysis of China's GDP Growth 40
II. Analysis of Development Status of Industrial Economy 41
III. Analysis of Total Investment in Fixed Assets 44
IV. Total Retail Sales of Consumer Goods 46
V. Analysis of Income Growth of Urban and Rural Residents 48
VI. Analysis of Changes in Consumer Prices 50
VII. Analysis of Development Status of Foreign Trade 52
Section II Analysis of Policy Environment for China’s Liver Disease Drug Market in 2013 53
Ⅰ. Industrial Competent Authorities 53
II. Industrial Supervision System 54
(I) Drug production and business license management 54
(Ⅱ)Pharmaceutical Production and Quality Management 54
(III) Drug Registration Management 54
(IV) Classification management of prescription and non-prescription drugs 55
(Ⅴ) Drug Pricing 55
(VI) Drug centralized purchasing and distribution 56
III. Main Laws, Regulations and Policies of the Industry 56
Section III Analysis of Policy Environment for China’s Liver Disease Drug Market in 2013 59
I. Analysis of Population Environment 59
II. Residents Health Care Spending 61
III. Analysis of Educational Environment 62
IV. Analysis of Cultural Environment 64
V. Analysis of Technical Environment 65
VI. Analysis of Ecological Environment 68
Section IV The level and features of liver disease medication technique 69
Chapter IV Hepatitis Incidence in China and Analysis of the Statistics of its Prevalence in 2013 70
Section I Statistics of the Viral Hepatitis Incidence in China in 2013 70
Ⅰ. Hepatitis A 70
II. Hepatitis B 70
III. Hepatitis C 71
IV. Hepatitis E 71
Section II Statistics of the Viral Hepatitis Death in China in 2013 71
Ⅰ. Hepatitis A 71
II. Hepatitis B 72
III. Hepatitis C 72
IV. Hepatitis E 72
Section III China As Also the High Incidence Area of Hepatitis B and Hepatitis E 73
I. The Total Prevalence Rate of Hepatitis C 73
II. The Total Prevalence Rate of .Hepatitis E 73
Chapter V Types of Liver medicine 75
Section I Antivirals 75
I. Interferon 75
II. Nucleotide Analogue Antiviral Drug 76
Section II Immunomodulating Drug 77
Section III Chinese Patent Medicine 79
I. Anti-Hepatic Fibrosis 79
II. Drugs improving immunity 81
Section IV Liver Protection Drugs 82
I. Vitamin 82
II. Drugs with Detoxification Function 82
III. Drugs promoting energy metabolism 83
IV. Drugs promoting the protein synthesis 83
Chapter VI Deep Research of China Liver Medication Market in 2013 84
Section I. China Liver Medication Market Scale 84
I. China Liver Medication Market Scale 84
II. Enormous patient group forms the striking liver therapeutic market. 85
Section II China Liver Medication Structure 85
Section III Analysis of Medication Market 86
Section IV Medicine for Hepatitis C and Analysis of Its Market Demand 87
Section V Hepatopathy Adjuvants Stimulate the Huge Market 88
Chapter VII Observation on Dynamics of Segment Market of Liver Disease Drugs 2013 89
Section I Analysis of Antiviral Market 89
I. Analysis of Anti-hepatitis Viral Drugs Market and the Latest Development 89
II. Market Competition Pattern 90
III. Overview, Market Analysis and Research Progress of Nucleoside Anti-hepatitis Viruses Drugs 91
Section II Market of Immunomodulating Drug 93
I. Market Analysis of Thymosin 93
II. Analysis of Market Prospect of Thymopentin 94
Section III Chinese Patent Medicine 95
I. Introduction of Traditional Chinese Medicine for Treatment of Hepatitis 95
II. Oxymatrine-Recommended Traditional Medicine for Anti-hepatitis B Virus 96
III. Chinese Patent Medicines Are Expected to Fill in the Blanks for the Treatment of Liver Diseases in US 97
Section IV Varieties and Market Analysis of Liver-protection Medicine 98
I. Introductions of Liver-protection Medicine 98
II. Common Liver Drugs Cases 98
III. Market Competition Tendency of China Liver Drugs 101
Chapter VIII China Hepatitis B Vaccine Market Analysis in 2013 103
Section I Domestic Market Profile of Hepatitis B Vaccine 103
Section II Analysis of China Hepatitis B Vaccine Market Demand 104
I. Analysis of China Hepatitis B Epidemic Situation 104
II. Wholesale Situation of HBV in China 104
III. China Hepatitis B Vaccine Market Analysis 105
Section III Genetic Engineered Hepatitis B Vaccine 106
I. Hepatitis B Vaccine Expressed by E. Coli System 107
II. Hepatitis B Vaccine Expressed by Yeast System 107
III. Hepatitis B Vaccine Expressed by Mammalian Cell System 108
IV. Prospect of Recombination of HBV 108
Chapter IX Comparative Analysis of Main Anti-Hepatitis Drugs in China in 2012-2013 110
Section I Nucleoside Drugs 110
I. Lamivudine 110
II. Adefovir Dipivoxil 111
III. Entecavir 111
IV. Telbivudine 111
V. Tenofovir Disoproxil Fumarate 111
Section II Interferon 112
SECTION III Analysis of Other Hot Hepatic Drugs Markets 112
I. Yishangfu Capsules 113
II. Selenium Yeast 113
III. Caoxian Hepatitis B Capsule 113
IV. Liver-protection Tablets 114
V. Inosine injection, inosine oral solution, inosine tablets 119
Chapter X Clinical Application of Liverish Research Results and Dynamic Tracing of the Newest Research Results 121
Section I The Research Process of Fatty Liver 121
Section II Hepatic Stem Cells Expected to Treat Hepatic Disease 121
Section III Researches and Clinical Applications of New Drug of Treatment for Hepatic Diseases 122
I. Process of Researching Hepatitis E Vaccine 122
II. Construction of China's First HCV Infectious Clone 123
Section IV New Research Achievements of CMT for Liver Diseases 124
I. Introduction of Chinese medicine liver disease treatment methods 124
II. Application of Certain Medications for the Treatment of Liver in CTM 125
III. Traditional Chinese medicine has its unique characteristic of curing anti-hepatic fibrosis 126
Chapter XI Analysis of Dynamic and Trend Competition for China’s Liver Disease Drug Market in 2013 128
Section I General Situation of Competition in China’s Liver Disease Drug in 2013 128
I. The Formation of Two Camps of Competition in Liver Disease Drug Market 128
(I) Imported Drugs and Home-made Drugs 128
(II)Chinese Patent Medicine and Western Medicine 129
II. Market Competition Degree 129
III. The Appearance of Liver Disease Brand in Market 130
Section II Analysis of Dynamic Competition of China’s Liver Disease Drug Market in 2013 130
I. Antiviral Drugs Will Remain the Major Choice of Hepatitis B Drug 130
II. Anti-virus Medicine 131
Section III Analysis of Competitiveness of Liver Disease Drug in Its Segmental Field in China in 2013 131
I. Liver-protection Medicine Market 131
II. Traditional Chinese Medicine for Antiviral 132
III. Analysis of Strength and Weakness of Immunomodulator in Competition 133
IV. Interferon Market 133
Section IV Analysis of Competition Trend of Liver Disease Drug Market in China 2014-2018 134
Chapter XII SWOT Analysis of China’s Liver Disease Drug Market in 2013 135
Section I Advantage 135
Section II Disadvantage 136
Section III Opportunity 136
Section IV Threat 138
Chapter XIII Analysis of Operation Conditions of Typical Domestic and Foreign Drugs Production Enterprises 140
Section I GlaxoSmithKline 140
I. Company Profile 140
II. Medicines for Hepatitis 141
III. Analysis of Enterprise Operation 141
IV. Analysis of Operation in China 141
V. Dynamic Analysis of Enterprise Development 142
Section II Roche 143
I. Company Profile 143
II. Medicines for Hepatitis 144
III. Analysis of Enterprise Operation 144
IV. Analysis of Development Strategy in China 145
V. Analysis of Corporate R & D Strength 145
Section III American Merck & Co 146
I. Company Profile 146
II. Medicines for Hepatitis 146
III. Analysis of Enterprise Operation 147
IV. Analysis of Operation in China 147
V. Dynamic Analysis of Enterprise Development 148
Section IV Beijing SL Pharmaceutical Co., Ltd. 148
I. Company Profile 148
II. Medicines for Hepatitis 149
III. Analysis of Enterprise Operation 150
IV. Distribution of Enterprise Marketing Network 152
V. Analysis of Enterprise Development Planning 152
Section V Inner Mongolia Furui Medical Science Co., Ltd. 154
I. Company Profile 154
II. Medicines for Hepatitis 155
III. Analysis of Enterprise Operation 156
IV. Distribution of Enterprise Marketing Network 157
V. Analysis of Company Development Strategy 158
Section VI Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 159
I. Company Profile 159
II. Medicines for Hepatitis 160
III. Analysis of Enterprise Operation 161
IV. Distribution of Enterprise Marketing Network 162
V. Analysis of Company Development Strategy 163
Section VII Fujian Cosunter Pharmaceutical Co., Ltd. 163
I. Company Profile 163
II. Medicines for Hepatitis 163
III. Analysis of Enterprise Operation 164
IV. Distribution of Enterprise Marketing Network 165
V. Analysis of Enterprise Strategic Planning 165
Section VIII TIPR Pharmaceutical Responsible Co., Ltd. 166
I. Company Profile 166
II. Medicines for Hepatitis 166
III. Analysis of Enterprise Operation 167
IV. Distribution of Enterprise Marketing Network 168
V. Analysis of Company Development Strategy 169
Chapter XIV Market Developing Prospects and Trends on China’s Medications for Hepatopathy from 2015 to 2020 170
Section I Market Forecasting on China’s Medications for Hepatopathy from 2015 to 2020 170
I. Forecast of Development Direction for Treatment on China's Hepatitis B 170
II. Market Size Forecasting on China’s Medications for Hepatopathy 170
III. Variation Trend of Profits on China’s Medications Industry for Hepatopathy 171
Section II Analysis of Investment Risk of China’s Liver Disease Drug Industry from 2015 to 2020 172
I. Macroeconomic Fluctuation Risk 172
II. Risk of New Products Development and Research 173
III. Products Marketing Risk 174
IV. Drug Price Adjustment Risk 174
V. Talent Competition Risks 175
Chapter XV Research and Analysis of China’s Liver Disease Drug Market Investment Feasibility from 2015 to 2020 176
Section I Overview of China’s Liver Disease Drug Market Investment in 2013 176
I. China’s Liver Disease Drug Investment Environment 176
II. Analysis of Entry Barriers of Liver Disease Drug Industry in China 178
(I) Administrative entry barriers 178
(II) Technology barriers 178
(III) Brand barriers 179
(IV) Finances barrier 179
Section II Analysis of Investment Opportunity of Liver Disease Drug Industry in 2014-2018 in China 179
I. Research of Investment Hot Spot in Liver Disease Drug Market 179
II. The Investment Potential of Adjutant Medicine Market of Liver Disease 180
Section III Analysis of Liver Disease Drug Enterprise Financing Channels and Selection in 2014-2018 181
I. Analysis of Liver Disease Drug Enterprise Financing Methods and Channels 181
II. Planning Enterprise Development Opportunity by Equity Financing 184
III. Make Use of the Government as a lever to Broaden the Channel of Capital Raising for Enterprises 191
IV. Moderate debt financing to optimize the enterprise's capital structure 192
V. Pay Attention to the Investment Trends of Private and Foreign Capital 195
Section IV Advice on Strategy of China Liver Disease Drug Industry Investment in 2014-2018 195
Section I Basic Explanation of Liver Disease 14
I. Classification and Harm of Liver Disease 14
II. Routes of Transmission 14
III. Symptoms of Liver Disease 15
IV. Development Stages of Liver Disease and Prevention and Treatment Measures 16
Section II Viral Hepatitis 17
I. Hepatitis A Virus (HAV) 17
II. Hepatitis B Virus (HBV) 18
III. Hepatitis C Virus (HCV) 20
IV. Hepatitis D Virus (HDV) 21
V. Hepatitis E Virus (HEV) 21
Section III Adiposis Hepatica and Hepatic Fibrosis 22
I. Adiposis Hepatica 22
II. Hepatic Fibrosis 22
Section IV The Clinical Features of Hepatoma 23
Section V Drug-induced Liver Injury 25
I. The Clinical Manifestations of Drug-induced Liver Injury 25
II. The Common Drugs That Are Easy to Cause the Damage of Liver Clinically 26
III. The Precautionary Measures of Drug-induced Liver Injury 27
Chapter II Analysis of the Operation Situation of Global Drugs for the Liver Disease Markets in 2013 29
Section I Analysis of Market Dynamics of Global Drugs for the Liver Disease Markets in 2013 29
I. Japan Has Exploited New Oral Hepatitis C Vaccine 29
II. Gilead Has Developed the New Generation of Hepatitis C Drugs 30
III. The Research of HCV Has Achieved New Breakthrough 30
Section II Analysis of Market Demand of Global Vaccine for the Hepatitis in 2013 31
I. Overview of Global Vaccine for the Hepatitis Market 31
II. Analysis of the Sales Status of the Global Vaccine for the Hepatitis 34
III. Demand Forecast of the Global Vaccine for the Hepatitis Market 34
Section III Analysis of the Application for Patent of the Global Hepatitis B 35
I. The Variation Trend of the Application Quantity for Patents 35
II. Description of Patent Application of Countries or Organizations 36
III. Description of Patent Application of Main Research and Development Production Agencies on Hepatitis B Vaccine 37
V. Analysis of patent technology life cycle 38
Chapter III Analysis of Market Development Environment of China’s Liver Disease Drug Industry in 2013-2014 40
Section I Analysis of China’s Macroeconomic Environment in 2014 40
I. Analysis of China's GDP Growth 40
II. Analysis of Development Status of Industrial Economy 41
III. Analysis of Total Investment in Fixed Assets 44
IV. Total Retail Sales of Consumer Goods 46
V. Analysis of Income Growth of Urban and Rural Residents 48
VI. Analysis of Changes in Consumer Prices 50
VII. Analysis of Development Status of Foreign Trade 52
Section II Analysis of Policy Environment for China’s Liver Disease Drug Market in 2013 53
Ⅰ. Industrial Competent Authorities 53
II. Industrial Supervision System 54
(I) Drug production and business license management 54
(Ⅱ)Pharmaceutical Production and Quality Management 54
(III) Drug Registration Management 54
(IV) Classification management of prescription and non-prescription drugs 55
(Ⅴ) Drug Pricing 55
(VI) Drug centralized purchasing and distribution 56
III. Main Laws, Regulations and Policies of the Industry 56
Section III Analysis of Policy Environment for China’s Liver Disease Drug Market in 2013 59
I. Analysis of Population Environment 59
II. Residents Health Care Spending 61
III. Analysis of Educational Environment 62
IV. Analysis of Cultural Environment 64
V. Analysis of Technical Environment 65
VI. Analysis of Ecological Environment 68
Section IV The level and features of liver disease medication technique 69
Chapter IV Hepatitis Incidence in China and Analysis of the Statistics of its Prevalence in 2013 70
Section I Statistics of the Viral Hepatitis Incidence in China in 2013 70
Ⅰ. Hepatitis A 70
II. Hepatitis B 70
III. Hepatitis C 71
IV. Hepatitis E 71
Section II Statistics of the Viral Hepatitis Death in China in 2013 71
Ⅰ. Hepatitis A 71
II. Hepatitis B 72
III. Hepatitis C 72
IV. Hepatitis E 72
Section III China As Also the High Incidence Area of Hepatitis B and Hepatitis E 73
I. The Total Prevalence Rate of Hepatitis C 73
II. The Total Prevalence Rate of .Hepatitis E 73
Chapter V Types of Liver medicine 75
Section I Antivirals 75
I. Interferon 75
II. Nucleotide Analogue Antiviral Drug 76
Section II Immunomodulating Drug 77
Section III Chinese Patent Medicine 79
I. Anti-Hepatic Fibrosis 79
II. Drugs improving immunity 81
Section IV Liver Protection Drugs 82
I. Vitamin 82
II. Drugs with Detoxification Function 82
III. Drugs promoting energy metabolism 83
IV. Drugs promoting the protein synthesis 83
Chapter VI Deep Research of China Liver Medication Market in 2013 84
Section I. China Liver Medication Market Scale 84
I. China Liver Medication Market Scale 84
II. Enormous patient group forms the striking liver therapeutic market. 85
Section II China Liver Medication Structure 85
Section III Analysis of Medication Market 86
Section IV Medicine for Hepatitis C and Analysis of Its Market Demand 87
Section V Hepatopathy Adjuvants Stimulate the Huge Market 88
Chapter VII Observation on Dynamics of Segment Market of Liver Disease Drugs 2013 89
Section I Analysis of Antiviral Market 89
I. Analysis of Anti-hepatitis Viral Drugs Market and the Latest Development 89
II. Market Competition Pattern 90
III. Overview, Market Analysis and Research Progress of Nucleoside Anti-hepatitis Viruses Drugs 91
Section II Market of Immunomodulating Drug 93
I. Market Analysis of Thymosin 93
II. Analysis of Market Prospect of Thymopentin 94
Section III Chinese Patent Medicine 95
I. Introduction of Traditional Chinese Medicine for Treatment of Hepatitis 95
II. Oxymatrine-Recommended Traditional Medicine for Anti-hepatitis B Virus 96
III. Chinese Patent Medicines Are Expected to Fill in the Blanks for the Treatment of Liver Diseases in US 97
Section IV Varieties and Market Analysis of Liver-protection Medicine 98
I. Introductions of Liver-protection Medicine 98
II. Common Liver Drugs Cases 98
III. Market Competition Tendency of China Liver Drugs 101
Chapter VIII China Hepatitis B Vaccine Market Analysis in 2013 103
Section I Domestic Market Profile of Hepatitis B Vaccine 103
Section II Analysis of China Hepatitis B Vaccine Market Demand 104
I. Analysis of China Hepatitis B Epidemic Situation 104
II. Wholesale Situation of HBV in China 104
III. China Hepatitis B Vaccine Market Analysis 105
Section III Genetic Engineered Hepatitis B Vaccine 106
I. Hepatitis B Vaccine Expressed by E. Coli System 107
II. Hepatitis B Vaccine Expressed by Yeast System 107
III. Hepatitis B Vaccine Expressed by Mammalian Cell System 108
IV. Prospect of Recombination of HBV 108
Chapter IX Comparative Analysis of Main Anti-Hepatitis Drugs in China in 2012-2013 110
Section I Nucleoside Drugs 110
I. Lamivudine 110
II. Adefovir Dipivoxil 111
III. Entecavir 111
IV. Telbivudine 111
V. Tenofovir Disoproxil Fumarate 111
Section II Interferon 112
SECTION III Analysis of Other Hot Hepatic Drugs Markets 112
I. Yishangfu Capsules 113
II. Selenium Yeast 113
III. Caoxian Hepatitis B Capsule 113
IV. Liver-protection Tablets 114
V. Inosine injection, inosine oral solution, inosine tablets 119
Chapter X Clinical Application of Liverish Research Results and Dynamic Tracing of the Newest Research Results 121
Section I The Research Process of Fatty Liver 121
Section II Hepatic Stem Cells Expected to Treat Hepatic Disease 121
Section III Researches and Clinical Applications of New Drug of Treatment for Hepatic Diseases 122
I. Process of Researching Hepatitis E Vaccine 122
II. Construction of China's First HCV Infectious Clone 123
Section IV New Research Achievements of CMT for Liver Diseases 124
I. Introduction of Chinese medicine liver disease treatment methods 124
II. Application of Certain Medications for the Treatment of Liver in CTM 125
III. Traditional Chinese medicine has its unique characteristic of curing anti-hepatic fibrosis 126
Chapter XI Analysis of Dynamic and Trend Competition for China’s Liver Disease Drug Market in 2013 128
Section I General Situation of Competition in China’s Liver Disease Drug in 2013 128
I. The Formation of Two Camps of Competition in Liver Disease Drug Market 128
(I) Imported Drugs and Home-made Drugs 128
(II)Chinese Patent Medicine and Western Medicine 129
II. Market Competition Degree 129
III. The Appearance of Liver Disease Brand in Market 130
Section II Analysis of Dynamic Competition of China’s Liver Disease Drug Market in 2013 130
I. Antiviral Drugs Will Remain the Major Choice of Hepatitis B Drug 130
II. Anti-virus Medicine 131
Section III Analysis of Competitiveness of Liver Disease Drug in Its Segmental Field in China in 2013 131
I. Liver-protection Medicine Market 131
II. Traditional Chinese Medicine for Antiviral 132
III. Analysis of Strength and Weakness of Immunomodulator in Competition 133
IV. Interferon Market 133
Section IV Analysis of Competition Trend of Liver Disease Drug Market in China 2014-2018 134
Chapter XII SWOT Analysis of China’s Liver Disease Drug Market in 2013 135
Section I Advantage 135
Section II Disadvantage 136
Section III Opportunity 136
Section IV Threat 138
Chapter XIII Analysis of Operation Conditions of Typical Domestic and Foreign Drugs Production Enterprises 140
Section I GlaxoSmithKline 140
I. Company Profile 140
II. Medicines for Hepatitis 141
III. Analysis of Enterprise Operation 141
IV. Analysis of Operation in China 141
V. Dynamic Analysis of Enterprise Development 142
Section II Roche 143
I. Company Profile 143
II. Medicines for Hepatitis 144
III. Analysis of Enterprise Operation 144
IV. Analysis of Development Strategy in China 145
V. Analysis of Corporate R & D Strength 145
Section III American Merck & Co 146
I. Company Profile 146
II. Medicines for Hepatitis 146
III. Analysis of Enterprise Operation 147
IV. Analysis of Operation in China 147
V. Dynamic Analysis of Enterprise Development 148
Section IV Beijing SL Pharmaceutical Co., Ltd. 148
I. Company Profile 148
II. Medicines for Hepatitis 149
III. Analysis of Enterprise Operation 150
IV. Distribution of Enterprise Marketing Network 152
V. Analysis of Enterprise Development Planning 152
Section V Inner Mongolia Furui Medical Science Co., Ltd. 154
I. Company Profile 154
II. Medicines for Hepatitis 155
III. Analysis of Enterprise Operation 156
IV. Distribution of Enterprise Marketing Network 157
V. Analysis of Company Development Strategy 158
Section VI Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 159
I. Company Profile 159
II. Medicines for Hepatitis 160
III. Analysis of Enterprise Operation 161
IV. Distribution of Enterprise Marketing Network 162
V. Analysis of Company Development Strategy 163
Section VII Fujian Cosunter Pharmaceutical Co., Ltd. 163
I. Company Profile 163
II. Medicines for Hepatitis 163
III. Analysis of Enterprise Operation 164
IV. Distribution of Enterprise Marketing Network 165
V. Analysis of Enterprise Strategic Planning 165
Section VIII TIPR Pharmaceutical Responsible Co., Ltd. 166
I. Company Profile 166
II. Medicines for Hepatitis 166
III. Analysis of Enterprise Operation 167
IV. Distribution of Enterprise Marketing Network 168
V. Analysis of Company Development Strategy 169
Chapter XIV Market Developing Prospects and Trends on China’s Medications for Hepatopathy from 2015 to 2020 170
Section I Market Forecasting on China’s Medications for Hepatopathy from 2015 to 2020 170
I. Forecast of Development Direction for Treatment on China's Hepatitis B 170
II. Market Size Forecasting on China’s Medications for Hepatopathy 170
III. Variation Trend of Profits on China’s Medications Industry for Hepatopathy 171
Section II Analysis of Investment Risk of China’s Liver Disease Drug Industry from 2015 to 2020 172
I. Macroeconomic Fluctuation Risk 172
II. Risk of New Products Development and Research 173
III. Products Marketing Risk 174
IV. Drug Price Adjustment Risk 174
V. Talent Competition Risks 175
Chapter XV Research and Analysis of China’s Liver Disease Drug Market Investment Feasibility from 2015 to 2020 176
Section I Overview of China’s Liver Disease Drug Market Investment in 2013 176
I. China’s Liver Disease Drug Investment Environment 176
II. Analysis of Entry Barriers of Liver Disease Drug Industry in China 178
(I) Administrative entry barriers 178
(II) Technology barriers 178
(III) Brand barriers 179
(IV) Finances barrier 179
Section II Analysis of Investment Opportunity of Liver Disease Drug Industry in 2014-2018 in China 179
I. Research of Investment Hot Spot in Liver Disease Drug Market 179
II. The Investment Potential of Adjutant Medicine Market of Liver Disease 180
Section III Analysis of Liver Disease Drug Enterprise Financing Channels and Selection in 2014-2018 181
I. Analysis of Liver Disease Drug Enterprise Financing Methods and Channels 181
II. Planning Enterprise Development Opportunity by Equity Financing 184
III. Make Use of the Government as a lever to Broaden the Channel of Capital Raising for Enterprises 191
IV. Moderate debt financing to optimize the enterprise's capital structure 192
V. Pay Attention to the Investment Trends of Private and Foreign Capital 195
Section IV Advice on Strategy of China Liver Disease Drug Industry Investment in 2014-2018 195
